Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways

Luigino Calzetta, Mario Cazzola, Clive P. Page, Paola Rogliani, Francesco Facciolo, Maria Gabriella Matera

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: The dual PDE3/4 inhibitor RPL 554 causes bronchodilation in patients with asthma or COPD and synergistically interacts with muscarinic receptor antagonists in relaxing human isolated bronchi in acute experimental settings. In the present study we investigated the long-lasting interaction between RPL554 and glycopyrronium by testing these drugs for their ability to relax both medium and small human isolated bronchi. Methods: The relaxant effect and duration of action of RPL554 and glycopyrronium, alone, or in combination, were studied on the contractile tone induced by electrical field stimulation (EFS) or carbachol in medium and small human isolated bronchi. Relaxation was expressed as percentage of maximal response and synergy analyzed by Bliss Independence theory. Results: Low concentrations of RPL554 and glycopyrronium induced maximal relaxation of medium bronchi at 160 ± 20 min and 50 ± 10 min, respectively, an effect detectable for at least 4 h. Maximal synergy was observed at =2 hrs (-71.4 ± 5.1%), and the combination extended the relaxation to at least 6 hrs, when the contractile tone was -41.2 ± 8.5% of the control responses. The combination induced the greatest effectiveness for EFS at 3 Hz and low-to-middle concentrations also produced significant synergism on small airways (21.1 ± 4.0%,P <0.05), compared with the additive response. The combination induced lumen area enhancement of 69.1 ± 2.4% (P <0.05), compared with the additive response (51.0 ± 5.4%). Conclusions: RPL554 and glycopyrronium demonstrated a synergistic interaction in relaxing both human medium and small isolated bronchi, in terms of peak relaxation and an extended duration of action, suggesting that this combination may have a beneficial role in the treatment of asthma or COPD.

Original languageEnglish
Pages (from-to)15-23
Number of pages9
JournalPulmonary Pharmacology and Therapeutics
Volume32
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Phosphodiesterase 3 Inhibitors
Phosphodiesterase 4 Inhibitors
Phosphoric Diester Hydrolases
Bronchi
Pharmacology
Chronic Obstructive Pulmonary Disease
Electric Stimulation
Asthma
Muscarinic Antagonists
Carbachol
Muscarinic Receptors
9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimidino(6,1-a)isoquinolin-4-one
Testing
Pharmaceutical Preparations

Keywords

  • Airway smooth muscle
  • Asthma
  • COPD
  • Glycopyrronium
  • Human isolated bronchi
  • Relaxant response
  • RPL554
  • Small airways
  • Synergistic interaction

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)
  • Biochemistry, medical

Cite this

Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. / Calzetta, Luigino; Cazzola, Mario; Page, Clive P.; Rogliani, Paola; Facciolo, Francesco; Matera, Maria Gabriella.

In: Pulmonary Pharmacology and Therapeutics, Vol. 32, 01.06.2015, p. 15-23.

Research output: Contribution to journalArticle

@article{4fc4b01d51e345c1b17f0fdaa78f7116,
title = "Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways",
abstract = "Background: The dual PDE3/4 inhibitor RPL 554 causes bronchodilation in patients with asthma or COPD and synergistically interacts with muscarinic receptor antagonists in relaxing human isolated bronchi in acute experimental settings. In the present study we investigated the long-lasting interaction between RPL554 and glycopyrronium by testing these drugs for their ability to relax both medium and small human isolated bronchi. Methods: The relaxant effect and duration of action of RPL554 and glycopyrronium, alone, or in combination, were studied on the contractile tone induced by electrical field stimulation (EFS) or carbachol in medium and small human isolated bronchi. Relaxation was expressed as percentage of maximal response and synergy analyzed by Bliss Independence theory. Results: Low concentrations of RPL554 and glycopyrronium induced maximal relaxation of medium bronchi at 160 ± 20 min and 50 ± 10 min, respectively, an effect detectable for at least 4 h. Maximal synergy was observed at =2 hrs (-71.4 ± 5.1{\%}), and the combination extended the relaxation to at least 6 hrs, when the contractile tone was -41.2 ± 8.5{\%} of the control responses. The combination induced the greatest effectiveness for EFS at 3 Hz and low-to-middle concentrations also produced significant synergism on small airways (21.1 ± 4.0{\%},P <0.05), compared with the additive response. The combination induced lumen area enhancement of 69.1 ± 2.4{\%} (P <0.05), compared with the additive response (51.0 ± 5.4{\%}). Conclusions: RPL554 and glycopyrronium demonstrated a synergistic interaction in relaxing both human medium and small isolated bronchi, in terms of peak relaxation and an extended duration of action, suggesting that this combination may have a beneficial role in the treatment of asthma or COPD.",
keywords = "Airway smooth muscle, Asthma, COPD, Glycopyrronium, Human isolated bronchi, Relaxant response, RPL554, Small airways, Synergistic interaction",
author = "Luigino Calzetta and Mario Cazzola and Page, {Clive P.} and Paola Rogliani and Francesco Facciolo and Matera, {Maria Gabriella}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.pupt.2015.03.007",
language = "English",
volume = "32",
pages = "15--23",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press",

}

TY - JOUR

T1 - Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways

AU - Calzetta, Luigino

AU - Cazzola, Mario

AU - Page, Clive P.

AU - Rogliani, Paola

AU - Facciolo, Francesco

AU - Matera, Maria Gabriella

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Background: The dual PDE3/4 inhibitor RPL 554 causes bronchodilation in patients with asthma or COPD and synergistically interacts with muscarinic receptor antagonists in relaxing human isolated bronchi in acute experimental settings. In the present study we investigated the long-lasting interaction between RPL554 and glycopyrronium by testing these drugs for their ability to relax both medium and small human isolated bronchi. Methods: The relaxant effect and duration of action of RPL554 and glycopyrronium, alone, or in combination, were studied on the contractile tone induced by electrical field stimulation (EFS) or carbachol in medium and small human isolated bronchi. Relaxation was expressed as percentage of maximal response and synergy analyzed by Bliss Independence theory. Results: Low concentrations of RPL554 and glycopyrronium induced maximal relaxation of medium bronchi at 160 ± 20 min and 50 ± 10 min, respectively, an effect detectable for at least 4 h. Maximal synergy was observed at =2 hrs (-71.4 ± 5.1%), and the combination extended the relaxation to at least 6 hrs, when the contractile tone was -41.2 ± 8.5% of the control responses. The combination induced the greatest effectiveness for EFS at 3 Hz and low-to-middle concentrations also produced significant synergism on small airways (21.1 ± 4.0%,P <0.05), compared with the additive response. The combination induced lumen area enhancement of 69.1 ± 2.4% (P <0.05), compared with the additive response (51.0 ± 5.4%). Conclusions: RPL554 and glycopyrronium demonstrated a synergistic interaction in relaxing both human medium and small isolated bronchi, in terms of peak relaxation and an extended duration of action, suggesting that this combination may have a beneficial role in the treatment of asthma or COPD.

AB - Background: The dual PDE3/4 inhibitor RPL 554 causes bronchodilation in patients with asthma or COPD and synergistically interacts with muscarinic receptor antagonists in relaxing human isolated bronchi in acute experimental settings. In the present study we investigated the long-lasting interaction between RPL554 and glycopyrronium by testing these drugs for their ability to relax both medium and small human isolated bronchi. Methods: The relaxant effect and duration of action of RPL554 and glycopyrronium, alone, or in combination, were studied on the contractile tone induced by electrical field stimulation (EFS) or carbachol in medium and small human isolated bronchi. Relaxation was expressed as percentage of maximal response and synergy analyzed by Bliss Independence theory. Results: Low concentrations of RPL554 and glycopyrronium induced maximal relaxation of medium bronchi at 160 ± 20 min and 50 ± 10 min, respectively, an effect detectable for at least 4 h. Maximal synergy was observed at =2 hrs (-71.4 ± 5.1%), and the combination extended the relaxation to at least 6 hrs, when the contractile tone was -41.2 ± 8.5% of the control responses. The combination induced the greatest effectiveness for EFS at 3 Hz and low-to-middle concentrations also produced significant synergism on small airways (21.1 ± 4.0%,P <0.05), compared with the additive response. The combination induced lumen area enhancement of 69.1 ± 2.4% (P <0.05), compared with the additive response (51.0 ± 5.4%). Conclusions: RPL554 and glycopyrronium demonstrated a synergistic interaction in relaxing both human medium and small isolated bronchi, in terms of peak relaxation and an extended duration of action, suggesting that this combination may have a beneficial role in the treatment of asthma or COPD.

KW - Airway smooth muscle

KW - Asthma

KW - COPD

KW - Glycopyrronium

KW - Human isolated bronchi

KW - Relaxant response

KW - RPL554

KW - Small airways

KW - Synergistic interaction

UR - http://www.scopus.com/inward/record.url?scp=84930510769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930510769&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2015.03.007

DO - 10.1016/j.pupt.2015.03.007

M3 - Article

C2 - 25899618

AN - SCOPUS:84930510769

VL - 32

SP - 15

EP - 23

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

ER -